Improving and targeting nicotine replacement therapy (NRT) are cost-effective strategies for reducing adverse health consequences for smokers. Treatment studies document the efficacy of pre-cessation NRT and support important roles for level of nicotine dependence and pre-cessation smoking reduction in successful quitting. However, prior work has not identified the optimal pre-cessation dose or means for personalizing NRT. Genome wide association has identified groups of genomic markers that are associated with successful quitting, allowing us to develop a v1.0 "quit success" genotype score. We now report influences of v1.0 quit success genotype score, level of dependence and pre-cessation smoking reduction in a smoking cessation trial that examined effects of 21 vs 42 mg/24 h pre-cessation NRT. 479 smokers were randomized to 21 or 42 mg NRT, initiated 2 weeks prior to target quit dates.
Cigarette smoking is a significant cause of premature death and disease 1 . Successfully quitting and maintaining abstinence reduce risks to smokers [2] [3] [4] . However, success rates following attempts to quit smoking remain modest. One year after unaided attempts to quit smoking, abstinence rates are less than 5% 5, 6 . Even with pharmacologic aids that include nicotine replacement therapy (NRT), bupropion and varenicline, long-term abstinence rates are less than 25% 7, 8 .
Pre-cessation NRT initiates nicotine patch treatment two weeks prior to a target quit date 9, 10 . The 21 mg/24 hour dose pre-cessation dose used to date is well tolerated by most smokers 9, 10 and consistently enhances quit rates: recent meta-analyses show a 1.8-2.2 fold greater likelihood of success than conventional NRT 11, 12 . However, neither dose/response data nor clear-cut recommendations for personalizing pre-cessation NRT have been reported.
More effective smoking cessation might result from personalizing existing treatments based on characteristics of individual smokers. Previous research has identified phenotypic and genotypic variables that might aid in predicting likelihood of success in smoking cessation and/or differential responses to different treatment regimens. In smoking cessation trials, smokers who score higher on the Fagerström Test for Nicotine Dependence (FTND), and thus display more prominent physiological dependence on nicotine, experience lower rates of success from conventional NRT regimens and may derive greater benefits from higher NRT doses [13] [14] [15] . In a trial of pre-cessation NRT with conventional, 21 mg/24h dosing, smokers with higher FTND scores displayed less benefit than those with lower scores 10 . We thus hypothesized, a priori, that more highly dependent smokers and smokers who find it more difficult to quit with conventional NRT doses might require higher NRT doses, both before and after their target quit dates.
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Aside from level of nicotine dependence, other features could help to personalize NRT. After initiation of pre-cessation NRT, individual differences in abilities to decrease end-expired air carbon monoxide (CO) concentrations provide measures of reduced ad lib smoking that strongly predict the ability to achieve abstinence 10 . Inherited predispositions are also likely to play large roles. Classical genetic studies strongly support the idea that individual differences in abilities to achieve abstinence have significant genetic determinants 16 . Genome-wide association and candidate gene molecular genetic studies of quit success have identified a number of candidate "quit success" alleles 17, 18 . No individual variant provides a large effect, raising several of the issues discussed in recent reviews [19] [20] [21] [22] .
Nevertheless, GWA datasets from multiple independent smoking cessation samples identify many of the same small chromosomal regions to extents that, overall, are virtually never found by chance 18 . Thus, as noted in a recent white paper, when "each individual has a constellation of many variants (we need to).. We thus now report a comparison of 21 and 42 mg/day pre-cessation NRT in smokers categorized based on levels of nicotine dependence, v1.0 quit success genotype scores and changes in expired air CO during the two week pre-cessation treatment period. We document the previously-reported predictive value of CO reductions during pre-cessation treatment. We also identify novel interactive effects of genotype score, dependence level and nicotine dose in influencing smoking abstinence outcomes in both
European-American and African-American smokers. We describe suggestions for personalized precessation NRT that arise from this work, especially as it is replicated in additional samples.
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MATERIALS AND METHODS
Study Design
The study had a randomized, double-blind, parallel-arm, placebo-controlled factorial design with two levels of nicotine dependence and two nicotine doses. Cigarette smokers interested in quitting were subdivided a priori into low-and high-dependence subgroups (FTND scores ≤ 6 or > 6, respectively 23 )
and were randomly assigned to 21 mg/24 h or 42 mg/24h nicotine patch doses.
Recruitment, eligibility and compensation
Adult smokers expressing a desire to quit smoking were recruited through newspaper, radio and television advertisements, flyers, and word-of-mouth and were screened by telephone and physical examination at one of four North Carolina centers. Participants provided written informed consent, reported smoking an average of > 10 cigarettes that each yielded > 0.5 mg nicotine per day, displayed end-expired air CO > 10 ppm and failed to display any exclusionary feature on history, physical exam or laboratory evaluation (Supplement 1). Participants were compensated up to $140 for seven sessions.
Study Procedures
After screening and enrollment in the study, participants returned to the research center for seven sessions ( Fig. 1) , during which brief (< 15 min) supportive counseling was provided, clinical trial materials were dispensed and dependent measures assessed. Dependent measures included self-reported smoking, end-expired air CO, withdrawal symptoms and other adverse effects.
Each participant wore two skin patches daily for eight weeks, beginning two weeks prior to the target quit data (Fig. 1 ). In the 21 mg nicotine dose condition, one active patch (GlaxoSmithKline) was applied All participants were provided with denicotinized cigarettes (< 0.05 mg nicotine yield; Vector Tobacco
Co., Mebane, NC) to smoke during the 2-week pre-cessation period, to minimize the likelihood of potential adverse effects of high dose NRT.
Genotyping and assignment of genetic background groups
DNA was extracted from blood, quantitated and genotyped using Affymetrix 6.0 microarrays as described (Supplement S2). Genotypes for each individual passed Affymetrix quality control metrics and provided calls for > 97% of SNP genotypes. Imputation using PLINK 24 with confidence threshold > 0.95 determined most missing genotype calls. nominally-highly-significant (P < 0.01) differences between successful vs unsuccessful quitters, weighting data from these SNPs based on strength and replicability of the associations (Supplement 3) 18 .
Analyses
Primary outcome: Continuous abstinence from the target quit date through the end of treatment (10 weeks) was assessed based on self reports of continuous abstinence (i.e., no lapses) that were confirmed by end-expired CO levels ≤ 10 ppm. Participants who withdrew from the study or were lost to follow-up were classified as nonabstinent. Secondary abstinence outcomes included a) 4-week continuous abstinence during weeks 7-10 after the target quit date, and b) 7 day, point abstinence at 6 months.
Logistic regression analyses were conducted to seek statistically-significant effects on quit success based on: nicotine patch dose (21 mg vs 42 mg), level of dependence (≤6 vs >6 FTND score), and v1.0 quitsuccess genotype scores (≤ median vs > median), with emphasis on interactions among these factors. In preplanned analyses, we compared individuals with upper-to lower half v1.0 quit success scores, seeking: a) to avoid any assumptions regarding the linearity of influences across the range of genotype scores; b) to ensure that equal numbers of subjects were classified "low" or "high" in each racial/ethnic subgroup; and c) to parallel the analyses used for FTND scores and changes in CO levels (see below). Based on results of interim analyses and our a priori hypotheses positing interactions between dose and level of dependence, the final analysis of the complete dataset (n =457) included the following terms:
nicotine dose (21 mg vs 42 mg); FTND dependence score (≤ 6 vs > 6); quit-success genotype score (≤ median vs > median); nicotine dose x dependence; and nicotine dose x dependence x genotype score.
Separate follow-up analyses for the European-and African-American samples explored the robustness of the nicotine dose x dependence x v1.0 genotype score interaction.
Frequencies with which adverse events occurred in the two nicotine dose conditions were compared using χ2 tests.
RESULTS
Most smokers who contacted the research center met eligibility criteria and were enrolled. Most enrollees participated successfully (Fig. 2) .
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Logistic regression of data from the primary outcome, 10-week continuous abstinence, yielded a significant three-way interaction between nicotine dose, dependence and quit-success genotype score (P = 0.015), exponentiated coefficient = 0.56 (95%CI = 0.35-0.91). The interaction noted in interim analysis of the initial set of subjects was also noted in separate analysis of data from the second half of the subject group (data not shown). In the entire group of subjects, the two-way interaction of nicotine dose and FTND score was also significant (P = 0.02), exponentiated coefficient = 1.78 (95% CI = 1.10-2.87). However, the pre-cessation decrease in CO did not explain all of the influences on quit success provided by other measures of individual differences. The three-way interaction of nicotine dose, FTND score and quit-success genotype score remained statistically significant even after inclusion of a term in the logistic regression model that reflected CO decreases (P = 0.04 for 10-week abstinence).
Adverse effects
Treatment was generally well tolerated. Three percent of participants withdrew from the study due to adverse effects. 
DISCUSSION
Nicotine replacement strategies, including pre-cessation NRT, aid smoking cessation with low cost and well-characterized safety profile. Personalizing NRT in ways that are informed by pre-cessation CO reductions and interactions between dependence and a v1.0 "quit success" genotype score appears to offer an attractive way of increasing cessation success for many smokers.
The plausibility of the results of this study is increased by several a priori considerations. The extent of nicotine dependence, assessed by FTND score, was likely, a priori, to influence success in quitting smoking, based on large amounts of evidence from many studies of smoking cessation, including some with pre-cessation NRT 5, 9 . Genetic influences on smoking cessation were also likely, a priori, to influence smoking cessation success, based on the substantial heritable influences documented in twin studies 27 . Retrospective molecular genetic studies identified SNP markers that provided nominallysignificant associations with quit success in one or more of three initially-reported samples 18 . Many of the genomic regions identified by these SNPs have also been identified by studies of quit success in three additional samples 28, 29 . Since none of these associations is of large magnitude, we assembled a v1.0 molecular genetic measure relevant to quit success by combining data from groups of SNPs that provide nominally-significant associations with this phenotype in three prior studies. This "baseline" characteristic of each participant was joined by data from CO reductions during pre-cessation NRT, since prior data supported the predictive power of such CO reductions. In addition to supporting a personalized treatment approach that takes into account baseline smoker characteristics, our results suggest that treatment algorithms could adapt therapeutic approaches based on smokers' initial reduction in ad lib smoking in response to pre-cessation nicotine patch treatment.
Smokers whose end-expired air CO level decreased >55.6% before the target quit date exhibited abstinence rates more than three times higher than those showing smaller decreases in CO. By rapidly identifying individuals who show insufficient CO reductions during pre-cessation NRT and hence are less likely to quit, we might avoid failed quit attempts through prompt application of alternative and/or more intensive treatments. Several such treatments, bupropion and varenicline, are more costly than NRT and appear to display greater risks [30] [31] [32] . A logical, stepped-care approach would thus entail initial use of pre-cessation NRT, assignment of nicotine dose based on dependence level and quit-success genotype scores, identification of individuals who do not reduce CO sufficiently and prompt 27 . Pre-cessation treatment is approved in Australia and the UK, and is under consideration by other regulatory authorities. The v1.0 genotype score, while displaying substantial promise, was based on data from European-American participants in only three sets of clinical trials 18 . We anticipate that the power of this approach will be further enhanced as data from additional studies allows us to improve this score. Finally, even after future results replicate those in the present report, it will be necessary to surmount barriers to acceptance prior to implementation in smoking cessation clinical trials and/or in clinical practice. These barriers include costs, perceptions about genotyping by researchers, physicians and patients, and other practical issues such as turnaround time for testing 33, 34 .
In summary, the present results provide support for a personalized and adaptive approach to smoking cessation treatment, which tailors the dose of NRT to the baseline phenotypic and genotypic 
